Loading
A phase 2 trial of Olmutinib in Non-small-cell lung cancer, run by Hanmi Pharmaceutical Company Limited, recorded as terminated on the registry.
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung is a phase 2 interventional study registered as NCT02485652 by Hanmi Pharmaceutical Company Limited, with 162 participants recorded, started 2015-08-31 and due to reach its primary completion in 2020-12-08. Interventions recorded: HM61713. Conditions recorded: Non Small Cell Lung Cancer.
Linked to the drug Olmutinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Hanmi Pharmaceutical, Olmutinib, Non-small-cell lung cancer and the tag pipeline.
Shares Olmutinib, Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.